TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-Provides-Update-on-Patent-Applications-for-Novel-Therapeutic-ARDS-003/default.aspx

Hoffen und beten leute. Das kann es sein..!

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-Provides-Update-on-Its-REDUVO-New-Drug-Submission/default.aspx?fbclid=IwAR3weOn1_zfYwrnEjpo-ZGCCiJBEXG2uCfl6JbGc8yXmiHxSqaCSZSnNGss&mibextid=Zxz2cZ

Langsam bleibt nichts mehr übrig 🙈

Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Zumindest neue Finanzmittel OTTAWA, ON, Aug. 11, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it has entered into a subscription agreement (the "Subscription Agreement") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean Inc. ("ABO"), whereby Tetra has agreed to issue to the Investor (i) senior unsecured convertible debentures ("Debentures") in the aggregate principal amount of up to $6,000,000, and (ii) warrants ("Warrants") to purchase common shares ("Common Shares") in the capital of the Company (collectively, the "Offering").

Mit mäßigem Erfolg 🙈

Cannabis-derived drug developer, Tetra Bio-Pharma Inc. (TBP), shared positive preclinical results from live COVID-19 infection studies and a septic lung model. The company stated these independently researched studies observed ARDS-003 and its potential to increase survival rates following a COVID-19 infection in a “humanized” mouse model. According to the company, ARDS-003 is a new drug which contains, a potent substance from a type two cannabinoid receptor, onternabez, which is an important immune system target. Tetra stated ARDS-003 can help regulate acute systemic inflammation and prevent sepsis, lung dysfunction, and organ damage. Allegedly, the studies demonstrated that ARDS-003 decreases hyperinflammatory response and slows disease progression. On top of this, Tetra shared that when using a recent septic lung model ARDS-003 produced a significant reduction of systemic cytokine and chemokine release. Lung tissue was improved, peripheral immune hyperactivation was reduced, and there was an improvement in capillary perfusion in lung tissue compared to controls. The company’s research team has also developed an oral formulation of the drug for an immediate release that can be used over time and may work well alongside other treatements.

Immerhin geht wieder etwas

Ich bin auch dabei. Habe vor einigen Monaten mein ansonsten eher konservatives Portfolio mit dieser "Gambling"-Aktie aufgeschmückt :)

Ok, scheinbar niemand mehr. Ciao

Trauerspiel, aber ich bin noch dabei 🥴 ein bisschen ruhig hier. Sonst noch jemand dabei ?

Ungewöhnlich 😕

OTTAWA, ON, May 31, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") of its holders of common shares (the "Shareholders") virtually on May 30, 2022. The Company is pleased to announce that all matters presented for approval at the Meeting were approved, except with respect to the proposed share consolidation of the issued and outstanding common shares of the Company, as further detailed below.